ASCO Registry Research Grant
Conquer Cancer, the ASCO Foundation, has established a new grants program to foster research that uses data derived from the American Society of Clinical Oncology (ASCO) Survey on COVID-19 in Oncology Registry (ASCO Registry) to inform the cancer community about the patterns of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 is impacting the delivery of cancer care and patient outcomes. The grant includes research funding of $30,000 per grant and access to deidentified ASCO Registry data. The grants are supported by Conquer Cancer’s COVID Impacts Cancer Fund.
The award provides funding to qualified clinical oncology, health services, or data science researchers to support the rapid analysis of ASCO Registry data, manuscript development, and the dissemination of findings into high-impact scientific, peer-reviewed manuscripts. Rapid discovery and translation of data into knowledge, as well as the dissemination and potential for implementation of evidence, are key to these efforts as the pandemic continues to impact patients with cancer.
The COVID-19 pandemic presents a unique opportunity to capture information on how a disease outbreak affects delivery of high-quality cancer care. While other entities have launched COVID-19 cancer registries, a majority of patients entered into the ASCO Registry are being treated at oncology practices that are independently operated or part of hospitals or health systems, rather than academic practices. ASCO’s registry collects information about patients undergoing treatment for cancer and with confirmed COVID-19 infection based on a positive test. As of February 24, 2021, the ASCO Registry includes 2240 patients contributed by 52 oncology practices.
Research supported by the ASCO Registry:
Applicants are invited to submit research proposals consistent with ASCO’s mission that can be addressed with ASCO Registry data.
ASCO’s Registry collects follow-up information on both COVID-19 disease and cancer outcomes at 30-day intervals for the first 90 days and 90-day intervals thereafter up to one year after COVID-19 diagnosis. The overarching goals of the ASCO Registry are to conduct analyses and to create a dataset that can be translated into evidence to be used to improve outcomes of cancer patients with COVID-19.
A detailed dataset description (which also includes the study schema and data capture forms) and summary of the ASCO Registry population characteristics, including demographic and clinical factors at the time of patient enrollment to the ASCO Registry are available on the ASCO website at www.asco.org/asco-coronavirus-information/coronavirus-registry. A copy of the ASCO Registry data dictionary is available upon request.
Note: Applicable data will be exported from the ASCO Registry on or around March 1 and no additional updates to the data will be provided; these data will be minimally cleaned and packaged for recipients of the grants. The recipient institutions must sign a Data Use Agreement before data is provided.
Types of outcomes and research foci that applicants may consider with the ASCO Registry dataset:
Evaluation of SARS-CoV-2 viral infection outcomes (hospitalizations (with or without ICU); need for ventilator; long-term symptoms; recovery; death related to COVID-19 disease complications) and cancer outcomes (disease progression, response to treatment, delays and discontinuations of cancer treatments, and death due to cancer).
Changes in patient care and outcomes over the course of the pandemic, including differences in COVID-19 interventions, differences in patterns of anti-cancer treatment, differences in patient outcomes.
Comparisons of select cancer patient subgroups to COVID-19 infection, more severe cases of COVID-19 (e.g., as defined by need for hospitalization, ICU care, or ventilation), cancer outcomes, or access to COVID-19 or cancer care. Subgroups may be defined by demographic characteristics (e.g., age, gender, race/ethnicity), clinical characteristics (e.g., treatment type at the time of diagnosis, cancer type, cancer stage), or interventions or care patterns related to COVID-19 (e.g., anti-COVID-19 treatments, use of telehealth).
Analyses that will inform future infectious disease outbreaks to minimize future disruptions in the provision of high-quality cancer care.
Note: A respondent may also develop a novel research question in any area not listed above if it is consistent with the ASCO Registry Study Schema and ASCO’s mission, and can be addressed with the ASCO Registry data. The ASCO Registry Study Schema and all registry data capture forms are available on the ASCO website at www.asco.org/asco-coronavirus-information/coronavirus-registry. A copy of the ASCO Registry data dictionary is available upon request.
The Research Team must meet the following criteria:
- The Research Team must include at least one oncology clinician who currently treats patients with cancer AND at least one data scientist/biostatistician. (Involvement of an infectious disease clinician or scientist, while optional, is encouraged.)
- The primary applicant/principal investigator (PI) must hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD) at the time of grant submission and may be an oncology clinician or data scientist/biostatistician as listed above.
- The PI must be an ASCO member or have submitted a membership application with the grant application. (To apply for new membership, or to renew an existing membership, go to http://www.asco.org/membership.)
The Sponsoring Institution* must meet the following criteria:
1. The Sponsoring Institution will administer the grant funds for the sole purpose of the project.
2. Applications may be submitted from the following entities:
- Higher Education Institutions
- Research Organizations
- Government Organizations (may include medical centers and hospitals that have access to resources and infrastructure to support a research project)
- Non-profit Organizations (includes medical societies or associations, advocacy organizations, foundations, hospitals)
- Non-Governmental Organizations.
3. The Sponsoring Institution must be based in the U.S.
4. The Sponsoring Institution must be able to comply with the conditions of the Data Use Agreement.
*Pharmaceutical companies and medical device manufacturers, their affiliates, and related foundations are not eligible.
The Conquer Cancer ASCO Registry Research Grant Review Committee reserves the right to evaluate and determine an applicant’s eligibility based on the information and justifications included in the application materials. Applicants who are uncertain about their eligibility are encouraged to contact firstname.lastname@example.org for clarification.
The full application must be submitted in accordance with the requirements and instructions of the Request for Proposals (RFP) by the application deadline. A Letter of Intent (LOI) is not required. All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted. If you have questions, please email email@example.com.
To download the RFP, please click here.
Full Application Due: April 12, 2021, 11:59 PM ET
Anticipated Notification of Award: May 20, 2021
Anticipated Grant Start Date: June 1, 2021
COVID Impacts Cancer Fund
This grant receives support that may result in a report to the CMS Open Payments website under the Physician Payments Sunshine Act. The supporting companies are required to report the amount of the grant, the names of physicians who are awarded this grant, and the names of their institutions. This information may appear on the Open Payments website. Find out more information about the Sunshine Act and CMS Open Payments program.